# Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer

> **NCT00179309** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 48 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Docetaxel
- **BIOLOGICAL:** PANVAC-V
- **BIOLOGICAL:** PANVAC-F
- **BIOLOGICAL:** Sargramostim

## Key facts

- **NCT ID:** NCT00179309
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2013-02
- **Final completion:** 2013-10
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2014-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00179309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00179309, "Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00179309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*